We are live on ! Find out more
RNTX icon

Rein Therapeutics

48 hedge funds and large institutions have $12.5M invested in Rein Therapeutics in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,142% more capital inflows, than outflows

Capital inflows: $3.49M | Capital outflows: $281K

200% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 4

180% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 5

20% more funds holding

Funds holding: 40 → 48 (+8)

4.66% more ownership

Funds ownership: 36.43% → 41.08% (+4.7%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
48
Holders Change
+8
Holders Change %
+20%
% of All Funds
0.58%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
12
Increased
14
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

RNTX Hedge Fund Activity: Q4 2025 in Review

48 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q4 2025, worth a combined $12.5M — up 29% from $9.8M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new RNTX positions and 4 closed out — a net gain of 8 holders — while 14 added to existing stakes and 5 trimmed.

The largest buyer was Voss Capital, adding an estimated $2.17M. The largest seller was Prosight Management, cutting an estimated $173K.

  • 48 institutional investors held Rein Therapeutics (RNTX) as of Q4 2025, up from 40 in Q3 2025.
  • Funds reported $12.5M of Rein Therapeutics stock for Q4 2025, up 29% quarter-over-quarter.
  • 12 funds opened new Rein Therapeutics positions in Q4 2025 and 4 closed out, a net change of +8 holders.
  • The largest Rein Therapeutics buyer in Q4 2025 was Voss Capital, an estimated $2.17M added.
  • The largest Rein Therapeutics seller in Q4 2025 was Prosight Management, an estimated $173K sold.

Based on aggregated 13F filings for Q4 2025.